Structural basis for the GSK-3β binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives
- 1 December 2005
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (23), 5129-5135
- https://doi.org/10.1016/j.bmcl.2005.08.077
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Pharmacological inhibitors of glycogen synthase kinase 3Trends in Pharmacological Sciences, 2004
- The glamour and gloom of glycogen synthase kinase-3Trends in Biochemical Sciences, 2004
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003
- Synthesis and in Vitro Characterization of 1-(4-Aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic Acid Derivatives. A New Class of Selective GSK-3 InhibitorsJournal of Medicinal Chemistry, 2003
- GSK-3: tricks of the trade for a multi-tasking kinaseJournal of Cell Science, 2003
- Progress toward virtual screening for drug side effectsProteins-Structure Function and Bioinformatics, 2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Designing specific protein kinase inhibitors:: insights from computer simulations and comparative sequence/structure analysisPharmacology & Therapeutics, 2002
- GSK3 takes centre stage more than 20 years after its discoveryBiochemical Journal, 2001
- Glycogen Synthase Kinase-3: Properties, Functions, and RegulationChemical Reviews, 2001